Find slides from real investment banking decks

Text slide 2 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Team slide 3 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Cover slide 4 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Text slide 5 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Comparison slide 6 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Text slide 7 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Text slide 8 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Framework slide 9 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Framework slide 10 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Team slide 11 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Section Divider slide 12 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Chart slide 13 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Chart slide 14 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Section Divider slide 15 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Table slide 16 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Table slide 17 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Cover slide 18 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Chart slide 19 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Chart slide 20 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Cover slide 21 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Text slide 22 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Comparison slide 23 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Comparison slide 24 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Closing slide 25 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy

Cover slide 26 from Alkermes — Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 (IL-2) Variant Immunotherapy